Eupraxia Pharmaceuticals Reports Durability of EP-104GI for Eosinophilic Esophagitis Treatment

VANCOUVER, British Columbia, Sept. 30, 2026 /CourierPR/ -- Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, has reported significant progress in its ongoing Phase 1b/2a RESOLVE trial for the treatment of eosinophilic esophagitis (EoE) with its drug EP-104GI. The latest data from the highest dose cohort of EP-104GI (Cohort 9) demonstrate durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission. This finding underscores the potential for a single annual dose to manage the condition effectively.

In the second highest dose group (Cohort 8b), patients continued to show meaningful histologic reductions in both inflammation and fibrosis, with Stage, 0.26 and Grade, 0.27 in the Eosinophilic Esophagitis Histology Scoring System (EoEHSS) at 36 weeks. These results are consistent across all cohorts analyzed to date, with 9 of 14 patients (64%) remaining in clinical remission 52 weeks after receiving a single administration of EP-104GI.

The Phase 1b/2a RESOLVE trial, which is evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with a history of confirmed active EoE, has shown promising results. In Cohort 8b, which received a 20 x 6 mg dose, the mean reduction in the Straumann Dysphagia Index (SDI) at 36 weeks was 3.3. Similarly, in Cohort 9, which received a 20 x 8 mg dose, the mean reduction in SDI at both 36 and 52 weeks was 3.0 at both timepoints.

Across cohorts 5-9, the clinical remission rates are as follows: - At 12 weeks, 53% (10/19) of patients achieved clinical remission. - At 24 weeks, 78% (14/18) of patients maintained clinical remission. - At 36 weeks, 61% (11/18) of patients maintained clinical remission. - At 52 weeks, 64% (9/14) of patients maintained clinical remission.

The tissue health outcomes, as measured by EoEHSS, have also shown improvement. In Cohort 8b, the mean EoEHSS Stage and Grade reductions at week 36 were -0.26 (SD=0.13) and -0.27 (SD=0.20), respectively. These findings suggest that EP-104GI may have the potential to treat patients suffering from EoE with a single annual dose.

Eupraxia Pharmaceuticals Inc. has not observed any treatment-related serious adverse events (SAEs) to date, nor have they seen adverse events related to corticosteroid exposure, such as abnormal changes to glucose levels. Oropharyngeal candidiasis, a commonly reported adverse event associated with the use of swallowed steroids, has not been observed in any of the 10 cohorts to date.

The Phase 2b portion of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting both the 120mg (20x6mg) and 160mg (20x8mg) doses. The interim data from this portion of the trial are expected in December 2026.

EoE is an inflammatory-mediated disease affecting more than 450,000 people in the United States, with the American Gastroenterological Association identifying it as a rapidly increasing condition in both incidence and prevalence. The impacts of both symptoms and interventions often lead to mental health issues, compounding the disease burden for both the healthcare system and the individual.

Eupraxia Pharmaceuticals Inc. is focused on developing locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The company's proprietary Diffusphere™ technology is designed to facilitate targeted drug delivery, supporting extended duration of effect and delivery of drugs in a hyper-localized fashion. The potential uses of this technology extend beyond pain and inflammatory gastrointestinal disease to oncology, infectious disease, and other critical disease areas.